First-line nivolumab plus ipilimumab in pleural mesothelioma: efficacy and safety data from the real-world MesoNet study
Background - Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited. - Methods - In this ret...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2025
|
| In: |
Lung cancer
Year: 2025, Jahrgang: 207, Pages: 1-10 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2025.108702 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.lungcan.2025.108702 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S016950022500594X 
|
| Verfasserangaben: | Rajiv Shah, Eva L. Buchmeier, Hans-Georg Kopp, Daniel C. Christoph, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V. Klotz, Inn Chung, Petros Christopoulos, Michael Thomas |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949869768 | ||
| 003 | DE-627 | ||
| 005 | 20260121111050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260121s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2025.108702 |2 doi | |
| 035 | |a (DE-627)1949869768 | ||
| 035 | |a (DE-599)KXP1949869768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Shah, Rajiv |d 1982- |e VerfasserIn |0 (DE-588)1074040481 |0 (DE-627)830206361 |0 (DE-576)435547690 |4 aut | |
| 245 | 1 | 0 | |a First-line nivolumab plus ipilimumab in pleural mesothelioma |b efficacy and safety data from the real-world MesoNet study |c Rajiv Shah, Eva L. Buchmeier, Hans-Georg Kopp, Daniel C. Christoph, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V. Klotz, Inn Chung, Petros Christopoulos, Michael Thomas |
| 264 | 1 | |c September 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 5. August 2025, Artikelversion: 7. August 2025 | ||
| 500 | |a Gesehen am 21.01.2026 | ||
| 520 | |a Background - Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited. - Methods - In this retrospective, multicenter study, the outcome and safety data for 135 consecutive patients with first-line nivolumab/ipilimumab were evaluated among 1,575 adult patients with PM from 12 German cancer centers. Radiologic response and progression were analyzed according to the revised modified RECIST criteria. - Results - The median overall survival (OS) was 13.1 months for the unselected real-world cohort, and 15.5 months for CM-743-eligible patients (16.7 months for the non-epithelioid and 10 months for the epithelioid subtypes). Patients who experienced partial responses to nivolumab/ipilimumab had significantly longer survival than those without (24 months vs. 10.3 months; p = 0.00026). 37 % of patients experienced immune-related adverse events (irAEs), among whom 58 % had grade 3/4 toxicity. IrAEs of any grade were associated with longer survival (17.3 months vs. 11.7 months for patients without irAEs; p = 0.022). Furthermore, grade 1/2 irAEs were associated with even better outcomes when compared to grade 3/4 toxicities (22.7 months vs. 16.7 months median OS) and absence of toxicity (p < 0.0167 for trend). - Conclusions - Overall survival with first-line nivolumab/ipilimumab in the real-world setting is comparable to the CM-743 results among trial-eligible patients, especially with non-epithelioid tumors, but shorter for the unselected cohort. IrAEs, in particular those of low-grade, were associated with better outcomes. In the absence of predictive biomarkers and with few therapeutic options available, both dual checkpoint blockade and platinum-pemetrexed chemotherapy remain viable first-line regimens. | ||
| 650 | 4 | |a Epithelioid | |
| 650 | 4 | |a First-line | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Mesothelioma | |
| 650 | 4 | |a Retrospective cohort | |
| 700 | 1 | |a Buchmeier, Eva L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kopp, Hans-Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Christoph, Daniel C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Griesinger, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reck, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffknecht, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuon, Jonas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frost, Nikolaj |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grohé, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Faehling, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Luan, Jingting |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roeper, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chesi, Paolo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blasi, Miriam |e VerfasserIn |0 (DE-588)1211411613 |0 (DE-627)1699293422 |4 aut | |
| 700 | 1 | |a Kimmich, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Olchers, Till |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Klotz, Laura Valentina |d 1983- |e VerfasserIn |0 (DE-588)143075101 |0 (DE-627)641874685 |0 (DE-576)334894921 |4 aut | |
| 700 | 1 | |a Chung, Inn |e VerfasserIn |0 (DE-588)1017963711 |0 (DE-627)679809740 |0 (DE-576)354707841 |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 207(2025) vom: Sept., Artikel-ID 108702, Seite 1-10 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a First-line nivolumab plus ipilimumab in pleural mesothelioma efficacy and safety data from the real-world MesoNet study |
| 773 | 1 | 8 | |g volume:207 |g year:2025 |g month:09 |g elocationid:108702 |g pages:1-10 |g extent:10 |a First-line nivolumab plus ipilimumab in pleural mesothelioma efficacy and safety data from the real-world MesoNet study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2025.108702 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S016950022500594X |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260121 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |e 50000PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 22 |y j | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 21 | ||
| 998 | |g 1017963711 |a Chung, Inn |m 1017963711:Chung, Inn |d 910000 |d 950000 |d 950900 |e 910000PC1017963711 |e 950000PC1017963711 |e 950900PC1017963711 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 20 | ||
| 998 | |g 143075101 |a Klotz, Laura Valentina |m 143075101:Klotz, Laura Valentina |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK143075101 |e 950000PK143075101 |e 950900PK143075101 |e 50000PK143075101 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 19 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 18 | ||
| 998 | |g 1211411613 |a Blasi, Miriam |m 1211411613:Blasi, Miriam |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB1211411613 |e 950000PB1211411613 |e 950900PB1211411613 |e 50000PB1211411613 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 15 | ||
| 998 | |g 1074040481 |a Shah, Rajiv |m 1074040481:Shah, Rajiv |d 910000 |d 950000 |d 950900 |e 910000PS1074040481 |e 950000PS1074040481 |e 950900PS1074040481 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1949869768 |e 4855590320 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"September 2025","dateIssuedKey":"2025"}],"id":{"eki":["1949869768"],"doi":["10.1016/j.lungcan.2025.108702"]},"person":[{"given":"Rajiv","family":"Shah","role":"aut","display":"Shah, Rajiv"},{"family":"Buchmeier","display":"Buchmeier, Eva L.","role":"aut","given":"Eva L."},{"given":"Hans-Georg","family":"Kopp","role":"aut","display":"Kopp, Hans-Georg"},{"given":"Daniel C.","family":"Christoph","display":"Christoph, Daniel C.","role":"aut"},{"role":"aut","display":"Griesinger, Frank","family":"Griesinger","given":"Frank"},{"family":"Reck","display":"Reck, Martin","role":"aut","given":"Martin"},{"family":"Hoffknecht","display":"Hoffknecht, Petra","role":"aut","given":"Petra"},{"given":"Jonas","display":"Kuon, Jonas","role":"aut","family":"Kuon"},{"family":"Frost","display":"Frost, Nikolaj","role":"aut","given":"Nikolaj"},{"given":"Christian","family":"Grohé","display":"Grohé, Christian","role":"aut"},{"given":"Martin","role":"aut","display":"Faehling, Martin","family":"Faehling"},{"given":"Jingting","family":"Luan","display":"Luan, Jingting","role":"aut"},{"given":"Julia","role":"aut","display":"Roeper, Julia","family":"Roeper"},{"family":"Chesi","display":"Chesi, Paolo","role":"aut","given":"Paolo"},{"family":"Blasi","role":"aut","display":"Blasi, Miriam","given":"Miriam"},{"given":"Martin","display":"Kimmich, Martin","role":"aut","family":"Kimmich"},{"display":"Olchers, Till","role":"aut","family":"Olchers","given":"Till"},{"family":"Bischoff","display":"Bischoff, Helge","role":"aut","given":"Helge"},{"role":"aut","display":"Klotz, Laura Valentina","family":"Klotz","given":"Laura Valentina"},{"given":"Inn","family":"Chung","display":"Chung, Inn","role":"aut"},{"family":"Christopoulos","role":"aut","display":"Christopoulos, Petros","given":"Petros"},{"display":"Thomas, Michael","role":"aut","family":"Thomas","given":"Michael"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Rajiv Shah, Eva L. Buchmeier, Hans-Georg Kopp, Daniel C. Christoph, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V. Klotz, Inn Chung, Petros Christopoulos, Michael Thomas"]},"title":[{"subtitle":"efficacy and safety data from the real-world MesoNet study","title_sort":"First-line nivolumab plus ipilimumab in pleural mesothelioma","title":"First-line nivolumab plus ipilimumab in pleural mesothelioma"}],"relHost":[{"id":{"zdb":["2025812-4"],"issn":["1872-8332"],"eki":["320649733"]},"part":{"extent":"10","pages":"1-10","volume":"207","year":"2025","text":"207(2025) vom: Sept., Artikel-ID 108702, Seite 1-10"},"origin":[{"dateIssuedDisp":"1985-","publisher":"Elsevier","publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1985"}],"disp":"First-line nivolumab plus ipilimumab in pleural mesothelioma efficacy and safety data from the real-world MesoNet studyLung cancer","title":[{"subtitle":"journal of the International Association for the Study of Lung Cancer","title":"Lung cancer","title_sort":"Lung cancer"}],"pubHistory":["1.1985 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320649733","note":["Gesehen am 20.02.20"]}],"recId":"1949869768","physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"note":["Online verfügbar: 5. August 2025, Artikelversion: 7. August 2025","Gesehen am 21.01.2026"],"language":["eng"]} | ||
| SRT | |a SHAHRAJIVBFIRSTLINEN2025 | ||